Breast Cancer Research Options
Genomic sequencing Assessment of 733 HER2-amplified Key and metastatic breast tumours uncovered considerable enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours addressed with prior anti-HER2 therapies121. These mutations, such as NF1 and HER2 activating mutations, contribute to resistance to tucatinib and nerati